Loading...
Loading...
Available on 1 platform
Sign in to view source links and access this dataset
Mingliang Liu's 2026 study integrates Mendelian randomization, kidney transcriptomics, and experimental validation to identify the transcription factor ChREBP (MLXIPL) as a driver of metabolic remodeling in diabetic kidney disease. The 16.3 KB document, shared under a CC-BY-4.0 license, details methods and results from genetic inference, network analyses, and validation in db/db mice and primary cells. This work provides a mechanistic rationale for targeting the MLXIPL/ChREBP axis to mitigate residual renal risk.
The dataset is a 16.3 KB DOCX document, not a typical structured data file; users should expect a research paper or supplementary material.